Comment
. 2003 Oct 18;362(9392):1333; author reply 1334.
doi: 10.1016/S0140-6736(03)14601-6.
ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit
- PMID: 14575997
- DOI: 10.1016/S0140-6736(03)14601-6
Item in Clipboard
Comment
ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit
Lancet.
.
No abstract available
Comment on
-
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.Lancet. 1992 Jan 4;339(8784):1-15. Lancet. 1992. PMID: 1345950 Review.
-
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.Lancet. 2003 Jun 21;361(9375):2099-106. doi: 10.1016/s0140-6736(03)13718-x. Lancet. 2003. PMID: 12826431 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
